miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: A retrospective analysis of the PETACC-8 trial

被引：0
|
作者：
Mathe, Y. Gaston [1 ]
Martin-Lanneree, S. [2 ]
Vazart, C. [2 ]
Fontaine, K. [2 ]
Mulot, C. [3 ]
Caumont, A. [4 ]
Montestruc, F. [4 ]
Le Malicot, K. [5 ]
Lepage, C. [6 ]
Taieb, J. [7 ]
Laurent-Puig, P. [8 ]
机构：
[1] IntegraGen SA, Mol Diagnost, Evry, France
[2] IntegraGen, R&D, Evry, France
[3] INSERM, U1147, Paris, France
[4] Biostat EXYSTAT, Malakoff, France
[5] FFCD, Biostat, Dijon, France
[6] CHU Dijon, Clin Oncol, Dijon, France
[7] Hop European George Pompidou, Dept Gastroenterol & Digest Oncol, Paris, France
[8] Paris Descartes Univ, UMR1147, Paris, France
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
521P
引用
收藏
页码：175 / 175
页数：1
相关论文
共 50 条
  • [1] A comprehensive predicting model of recurrence in stage III colon cancer from PETACC-8 trial
    Gallois, C.
    Sroussi, M.
    Mouillet-Richard, S.
    Mulot, C.
    Dourthe, L. M.
    Mazard, T.
    Jary, M.
    de la Fouchardiere, C.
    Lecaille, C.
    Lahlou, W.
    Tabernero, J.
    van Laethem, J-L.
    Lepage, C.
    Emile, J. F.
    Taieb, J.
    de Reynies, A.
    Laurent-Puig, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S684 - S685
  • [2] Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials
    Auclin, Edouard
    Taieb, Julien
    Lepage, Come
    Aparicio, Thomas
    Faroux, Roger
    Mini, Enrico
    Folprecht, Gunnar
    Salazar, Ramon
    Benetkiewicz, Magdalena
    Banzi, Maria
    Louvet, Christophe
    Van Laethem, Jean-Luc
    Tabernero, Josep
    Hickish, Tamas
    de Gramont, Aimery
    Andre, Thierry
    Vernerey, Dewi
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2019, 28 (07) : 1153 - 1161
  • [3] Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial
    Taieb, Julien
    Puig, Pierre Laurent
    Bedenne, Laurent
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (02) : 183 - 189
  • [4] Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial
    Bruzzi, M.
    Auclin, E.
    Lo Dico, R.
    Voron, T.
    Karoui, M.
    Espin, E.
    Cianchi, F.
    Weitz, J.
    Buggenhout, A.
    Malafosse, R.
    Denimal, F.
    Le Malicot, K.
    Vernerey, D.
    Douard, R.
    Emile, J. F.
    Lepage, C.
    Laurent-Puig, P.
    Taieb, J.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (11) : 3561 - 3567
  • [5] Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
    Taieb, Julien
    Tabernero, Josep
    Mini, Enrico
    Subtil, Fabien
    Folprecht, Gunnar
    Van Laethem, Jean-Luc
    Thaler, Josef
    Bridgewater, John
    Petersen, Lone Norgard
    Blons, Helene
    Collette, Laurence
    Van Cutsem, Eric
    Rougier, Philippe
    Salazar, Ramon
    Bedenne, Laurent
    Emile, Jean-Francois
    Laurent-Puig, Pierre
    Lepage, Come
    LANCET ONCOLOGY, 2014, 15 (08): : 862 - 873
  • [6] Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial
    M. Bruzzi
    E. Auclin
    R. Lo Dico
    T. Voron
    M. Karoui
    E. Espin
    F. Cianchi
    J. Weitz
    A. Buggenhout
    R. Malafosse
    F. Denimal
    K. Le Malicot
    D. Vernerey
    R. Douard
    J. F. Emile
    C. Lepage
    P. Laurent-Puig
    J. Taieb
    Annals of Surgical Oncology, 2019, 26 : 3561 - 3567
  • [7] Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab A Post Hoc Analysis of the PETACC-8 Trial
    Taieb, Julien
    Zaanan, Aziz
    Le Malicot, Karine
    Julie, Catherine
    Blons, Helene
    Mineur, Laurent
    Bennouna, Jaafar
    Tabernero, Josep
    Mini, Enrico
    Folprecht, Gunnar
    Van Laethem, Jean Luc
    Lepage, Come
    Emile, Jean-Francois
    Laurent-Puig, Pierre
    JAMA ONCOLOGY, 2016, 2 (05) : 643 - 652
  • [8] Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
    Blons, H.
    Emile, J. F.
    Le Malicot, K.
    Julie, C.
    Zaanan, A.
    Tabernero, J.
    Mini, E.
    Folprecht, G.
    Van Laethem, J. L.
    Thaler, J.
    Bridgewater, J.
    Norgard-Petersen, L.
    Van Cutsem, E.
    Lepage, C.
    Zawadi, M. A.
    Salazar, R.
    Laurent-Puig, P.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2014, 25 (12) : 2378 - 2385
  • [9] Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies.
    Auclin, Edouard
    Taieb, Julien
    Lepage, Come
    Aparicio, Thomas
    Faroux, Roger
    Mini, Enrico
    Folprecht, Gunnar
    Salazar, Ramon
    Banzi, Maria
    Louvet, Christophe
    Van Laethem, Jean-Luc
    Tabernero, Josep
    Hickish, Tamas
    De Gramont, Aimery
    Andre, Thierry
    Vernerey, Dewi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Overall survival (OS) and updated disease-free survival (DFS) results of the NSABP C-08 trial assessing bevacizumab (B) in stage II and III colon cancer
    Allegra, C. J.
    Yothers, G. A.
    O'Connell, M. J.
    Sharif, S.
    Petrelli, N. J.
    Colangelo, L. H.
    Wolmark, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345